Zoetis Inc. (ZTS) PT Set at $80.00 by Cowen and Company
Zoetis Inc. (NYSE:ZTS) received a $80.00 price target from investment analysts at Cowen and Company in a note issued to investors on Friday. The brokerage currently has a “buy” rating on the stock. Cowen and Company’s target price would suggest a potential upside of 13.62% from the stock’s previous close.
Other analysts have also recently issued research reports about the stock. Cantor Fitzgerald reaffirmed a “buy” rating and set a $75.00 price target on shares of Zoetis in a research report on Wednesday, September 6th. Stifel Nicolaus reiterated a “buy” rating and set a $65.00 price objective on shares of Zoetis in a report on Friday, September 1st. Piper Jaffray Companies set a $73.00 price objective on shares of Zoetis and gave the company a “buy” rating in a report on Friday, August 25th. BidaskClub lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 20th. Finally, Zacks Investment Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price objective on the stock in a report on Thursday, October 12th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $67.65.
Shares of Zoetis (ZTS) opened at $70.41 on Friday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80. Zoetis has a one year low of $48.55 and a one year high of $70.49. The firm has a market cap of $33,925.01, a price-to-earnings ratio of 31.94, a price-to-earnings-growth ratio of 2.03 and a beta of 1.02.
Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.02. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. Zoetis’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.52 earnings per share. sell-side analysts expect that Zoetis will post 2.37 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Zoetis Inc. (ZTS) PT Set at $80.00 by Cowen and Company” was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/zoetis-inc-zts-pt-set-at-80-00-by-cowen-and-company/1709175.html.
Several institutional investors have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. raised its position in Zoetis by 16.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock worth $100,000 after purchasing an additional 230 shares during the period. Harfst & Associates Inc. raised its position in Zoetis by 16.1% in the 2nd quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock worth $117,000 after purchasing an additional 260 shares during the period. Almanack Investment Partners LLC. purchased a new position in Zoetis in the 2nd quarter worth $119,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its position in Zoetis by 251.9% in the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock worth $121,000 after purchasing an additional 1,360 shares during the period. Finally, Peddock Capital Advisors LLC purchased a new position in Zoetis in the 2nd quarter worth $140,000. Hedge funds and other institutional investors own 92.44% of the company’s stock.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.